Search results for "Intrahepatic cholangiocarcinoma"

showing 10 items of 35 documents

Repeated resection for recurrent intrahepatic cholangiocarcinoma: A retrospective German multicentre study.

2020

Background Tumour recurrence is common after resection of intrahepatic cholangiocarcinoma (ICC). Repeated resection is a potential curative treatment, but outcomes are not well-defined thus far. The aim of this retrospective multicentre cohort study was to show the feasibility and survival of repeated resection of ICC recurrence. Methods Data were collected from 18 German hepato-pancreatico-biliary centres for patients who underwent repeated exploration of recurrent ICC between January 2008 and December 2017. Primary end points were overall (OS) and recurrence-free survival from the day of primary and repeated resection. Results Of 156 patients who underwent repeated exploration for recurre…

medicine.medical_specialtyResectionCholangiocarcinomaCohort Studies03 medical and health sciences0302 clinical medicineMedicineHepatectomyHumansIntrahepatic CholangiocarcinomaRetrospective StudiesHepatologybusiness.industryPrimary resectionRecurrent Intrahepatic Cholangiocarcinoma3. Good healthTumor recurrenceSurgeryTreatment OutcomeBile Duct NeoplasmsMedian timeCurative treatment030220 oncology & carcinogenesis030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessCohort studyLiver international : official journal of the International Association for the Study of the LiverReferences
researchProduct

Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study

2019

Abstract Background For complete removal of intrahepatic cholangiocarcinoma (ICC), extended resection is often necessary. Information on the influence of visceral or vascular extension, extended resection, or postoperative morbidity on survival is scarce. The aim of this study was to show the impact of an aggressive surgical attitude on morbidity, mortality, and long-term outcome. Materials and methods All explorations at a high volume tertiary center between January 2008 and June 2018 with histological proof of ICC were included in this retrospective cohort study. The primary outcome was the extent of resection, secondary outcomes were postoperative morbidity, and their influence on overal…

Malemedicine.medical_specialtySingle CenterResectionCholangiocarcinomaPrimary outcomeOverall survivalHepatectomyHumansMedicineIn patientPostoperative PeriodIntrahepatic CholangiocarcinomaAgedRetrospective Studiesbusiness.industryLiver NeoplasmsRetrospective cohort studyGeneral MedicineMiddle AgedSurvival AnalysisSurgeryBile Ducts IntrahepaticTreatment OutcomeBile Duct NeoplasmsFemaleSurgeryMorbiditybusinessCohort studyInternational Journal of Surgery
researchProduct

Influence of Lymphangio (L), Vascular (V), and Perineural (Pn) Invasion on Recurrence and Survival of Resected Intrahepatic Cholangiocarcinoma

2021

(1) Background: Intrahepatic cholangiocarcinoma (ICC) is a rare malignancy. Besides tumor, nodal, and metastatic status, the UICC TNM classification describes further parameters such as lymphangio- (L0/L1), vascular (V0/V1/V2), and perineural invasion (Pn0/Pn1). The aim of this study was to analyze the influence of these parameters on recurrence and survival. (2) Methods: All surgical explorations for patients with ICC between January 2008 and June 2018 were collected and further analyzed in our institutional database. Statistical analyses focused on perineural, lymphangio-, and vascular invasion examined histologically and their influence on tumor recurrence and survival. (3) Results: Of 2…

medicine.medical_specialtyPerineural invasionMalignancyGastroenterologysurvivalArticleResectionVascular invasion03 medical and health sciences0302 clinical medicineintrahepatic cholangiocarcinomaInternal medicineStatistical analysesmedicineOverall survivalvascular invasionliver surgeryIntrahepatic Cholangiocarcinomabusiness.industryRlymphangioinvasionGeneral Medicineperineural invasionmedicine.diseaseTumor recurrence030220 oncology & carcinogenesisMedicine030211 gastroenterology & hepatologybusinessJournal of Clinical Medicine
researchProduct

The addition of TACE to palliative chemotherapy is associated with extended survival in unresectable intrahepatic cholangiocarcinoma

2021

Oncologymedicine.medical_specialtybusiness.industryInternal medicinemedicinePalliative chemotherapybusinessIntrahepatic CholangiocarcinomaViszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV)
researchProduct

Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling

2021

Simple Summary Intrahepatic cholangiocarcinoma is a rare disease with increasing incidence and mortality still characterized by an insufficient clinical outcome. Growing attention has recently surrounded this disease, and liver transplantation has emerged as a novel curative treatment for cholangiocarcinoma, along with a better understanding of genetic alterations potentially capable of driving tumorigenesis. The aim of this paper is to present a clinical description of our case series of patients affected by intrahepatic cholangiocarcinoma and by mixed forms of hepatocellular and cholangiocellular carcinoma, together with a genomic profiling of mutations occurring in a panel of genes relev…

Cancer ResearchLiver tumorliver transplantationbusiness.industrymedicine.medical_treatmentWnt signaling pathwayCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensLiver transplantationmedicine.diseasemedicine.disease_causeArticlenext-generation sequencing.Oncologyintrahepatic cholangiocarcinomamedicineCancer researchnext-generation sequencingKRASCarcinogenesisbusinessPI3K/AKT/mTOR pathwayIntrahepatic CholangiocarcinomaRC254-282intrahepatic cholangiocarcinoma; liver transplantation; next-generation sequencingCancers
researchProduct

Hepatocellular carcinoma (HCC) vs. non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018

2019

PURPOSE: The Liver Imaging Reporting and Data System (LI-RADS) was created to standardize the diagnostic criteria for hepatocellular carcinoma (HCC), and has undergone multiple revisions including a recent update in 2018 (v2018). The primary aim of this study was to determine the diagnostic performance and interrater reliability (IRR) of LI-RADS v2018 for distinguishing HCC from non-HCC primary hepatic malignancy in patients ‘at-risk’ for HCC. A secondary aim was to assess the impact of changes introduced in the v2018 diagnostic algorithm. METHODS: This retrospective study combined a 10-year experience of pathologically-proven primary liver malignancies from two large liver transplant cente…

AdultMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularUrologyMalignancySensitivity and SpecificityArticle030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineInternal medicineImage Interpretation Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingIn patientLiver imagingAgedRetrospective StudiesAged 80 and overCirrhosiRadiological and Ultrasound Technologybusiness.industryLiver NeoplasmsGastroenterologyReproducibility of ResultsRetrospective cohort studyHepatologyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingInterrater reliabilitydigestive system diseasesCombined hepatocellular-cholangiocarcinoma (cHCC-CCA)030220 oncology & carcinogenesisHepatocellular carcinomaCohortLI-RADSFemaleRadiologybusinessTomography X-Ray ComputedIntrahepatic cholangiocarcinoma (iCCA)Algorithms
researchProduct

The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma

2021

Incidence and mortality of intrahepatic cholangiocarcinoma (iCCA) have been increasing continuously. Recent studies suggest that the combination of palliative chemotherapy (pCTX) and transarterial chemoembolization (TACE) improves overall survival (OS). This study aimed to evaluate the outcome of patients treated with TACE and pCTX in unresectable iCCA at our tertiary care center. A group of 14 patients was treated with both pCTX and TACE. The non-randomized control group of 59 patients received pCTX alone. Patients received a median of two pCTX lines in both groups. Those treated with TACE underwent a median number of 3.5 sessions. Median OS from the time of unresectability was 26.2 months…

medicine.medical_specialtycombined modality therapymedicine.medical_treatmentchemotherapyGastroenterologysurvivalArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineCombined Modality TherapyStage (cooking)chemoembolizationIntrahepatic CholangiocarcinomaChemotherapyPerformance statusbusiness.industryIncidence (epidemiology)RGeneral MedicinePalliative chemotherapy030220 oncology & carcinogenesisPropensity score matchingMedicine030211 gastroenterology & hepatologybusinesscholangiocarcinomaJournal of Clinical Medicine
researchProduct

Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience.

2012

Abstract Aims The aim of this study is to evaluate factors associated with the outcome after surgical resection and to compare the efficacy of surgery to transarterial chemoembolisation (TACE) in patients with advanced intrahepatic cholangiocarcinoma (IHC). Materials and methods 273 patients with IHC treated in our department between 1997 and 2012 were included in our study. Patients were divided according to therapy into surgical ( n  = 130), TACE ( n  = 32), and systemic chemotherapy/best supportive care ( n  = 111) groups. Clinicopathological characteristics and survival were reviewed retrospectively. Results The 1-, 3-, and 5-year survival rates in patients after surgical resection were…

AdultLiver CirrhosisMalemedicine.medical_specialtyKaplan-Meier EstimateSingle CenterCholangiocarcinomaHepatic ArteryAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansChemoembolization TherapeuticLymph nodeIntrahepatic CholangiocarcinomaAgedRetrospective StudiesAged 80 and overUnivariate analysisAnalysis of Variancebusiness.industryBile ductLiver NeoplasmsRetrospective cohort studyGeneral MedicineMiddle AgedSurgerymedicine.anatomical_structureBile Ducts IntrahepaticTreatment OutcomeOncologyBile Duct NeoplasmsChemotherapy AdjuvantResection marginSurgeryFemalePositive Surgical MarginbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Intrahepatic cholangiocarcinoma: Limitations for resectability, current surgical concepts and future perspectives.

2020

Intrahepatic cholangiocarcinoma (iCCA) is the second most common hepatic malignancy and its incidence has been shown to increase significantly during the past decades. Complete surgical resection is currently acknowledged as the only curative treatment option able to provide adequate long-term outcomes. We herein review technical, functional and oncologic limitations for resectability, discuss current surgical aspects as well as highlight the fields in which future research and practice should focus on in order to ameliorate long-term outcomes in patients with iCCA.

Surgical resectionmedicine.medical_specialty030230 surgeryResectionBile duct cancerCholangiocarcinomaNeoplasms Multiple Primary03 medical and health sciences0302 clinical medicinePostoperative ComplicationsmedicineHepatectomyHepatic InsufficiencyHumansIn patientNeoplasm InvasivenessIntensive care medicineIntrahepatic Cholangiocarcinomabusiness.industryMargins of ExcisionGeneral Medicinemedicine.diseaseHepatic malignancyNeoadjuvant TherapyLiver TransplantationBile Ducts IntrahepaticOncologyBile Duct NeoplasmsCurative treatment030220 oncology & carcinogenesisBlood VesselsLymph Node ExcisionSurgeryLaparoscopyNeoplasm Recurrence LocalbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Should all intrahepatic cholangiocarcinomas receive neoadjuvant chemotherapy before resection?

2021

medicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentMEDLINEAntineoplastic AgentsCombined Modality TherapyNeoadjuvant TherapyResectionCholangiocarcinomaText miningBile Duct NeoplasmsLiverPreoperative PeriodmedicineHumansSurgeryRadiologyIntrahepatic CholangiocarcinomasbusinessNeoadjuvant therapyThe British journal of surgery
researchProduct